Aman P Singh

List of Publications by Year
in descending order

		759233		1058476
14 papers	498 citations	12 h-index	14 g-index	

15 all docs	15 docs citations	15 times ranked	415 citing authors

#	Article	IF	Citations
1	Model‐Based Cellular Kinetic Analysis of Chimeric Antigen Receptor‐T Cells in Humans. Clinical Pharmacology and Therapeutics, 2021, 109, 716-727.	4.7	49
2	Bench‐to‐bedside translation of chimeric antigen receptor (CAR) T cells using a multiscale systems pharmacokinetic‐pharmacodynamic model: A case study with anti‐BCMA CAR‐T. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 362-376.	2.5	23
3	Development of a quantitative relationship between CAR-affinity, antigen abundance, tumor cell depletion and CAR-T cell expansion using a multiscale systems PK-PD model. MAbs, 2020, 12, 1688616.	5.2	71
4	Antibody Coadministration as a Strategy to Overcome Binding-Site Barrier for ADCs: a Quantitative Investigation. AAPS Journal, 2020, 22, 28.	4.4	32
5	Evolution of the Systems Pharmacokinetics-Pharmacodynamics Model for Antibody-Drug Conjugates to Characterize Tumor Heterogeneity and *In Vivo* Bystander Effect. Journal of Pharmacology and Experimental Therapeutics, 2020, 374, 184-199.	2.5	20
6	A "Dual"-Cell-Level Systems PK-PD Model to Characterize the Bystander Effect of ADC. Journal of Pharmaceutical Sciences, 2019, 108, 2465-2475.	3.3	16
7	A Cell-Level Systems PK-PD Model to Characterize In Vivo Efficacy of ADCs. Pharmaceutics, 2019, 11, 98.	4.5	12
8	Utility of PK-PD Modeling and Simulation to Improve Decision Making for Antibody-Drug Conjugate Development. Cancer Drug Discovery and Development, 2018, , 73-97.	0.4	3
9	Application of a PK-PD Modeling and Simulation-Based Strategy for Clinical Translation of Antibody-Drug Conjugates: a Case Study with Trastuzumab Emtansine (T-DM1). AAPS Journal, 2017, 19, 1054-1070.	4.4	31
10	Measurement and Mathematical Characterization of Cell-Level Pharmacokinetics of Antibody-Drug Conjugates: A Case Study with Trastuzumab-vc-MMAE. Drug Metabolism and Disposition, 2017, 45, 1120-1132.	3.3	31
11	Evolution of Antibody-Drug Conjugate Tumor Disposition Model to Predict Preclinical Tumor Pharmacokinetics of Trastuzumab-Emtansine (T-DM1). AAPS Journal, 2016, 18, 861-875.	4.4	37
12	Quantitative characterization of in vitro bystander effect of antibody-drug conjugates. Journal of Pharmacokinetics and Pharmacodynamics, 2016, 43, 567-582.	1.8	81
13	Application of Pharmacokinetic-Pharmacodynamic Modeling and Simulation for Antibody-Drug Conjugate Development. Pharmaceutical Research, 2015, 32, 3508-3525.	3.5	44
14	Quantitative Prediction of Human Pharmacokinetics for mAbs Exhibiting Target-Mediated Disposition. AAPS Journal, 2015, 17, 389-399.	4.4	47